Notice of Availability for Exclusive, Non-Exclusive, or Partially-Exclusive Licensing of an Invention Concerning the Guanidylimidazole and Guanidylimidazoline Derivatives as Antimalarial Agents, Synthesis of and Methods of Use Thereof, 38122 [2011-16291]

Download as PDF 38122 Federal Register / Vol. 76, No. 125 / Wednesday, June 29, 2011 / Notices Notice. DEPARTMENT OF DEFENSE ACTION: Department of the Army SUMMARY: Notice of Availability for Exclusive, Non-Exclusive, or Partially-Exclusive Licensing of an Invention Concerning the Guanidylimidazole and Guanidylimidazoline Derivatives as Antimalarial Agents, Synthesis of and Methods of Use Thereof Department of the Army, DoD. Notice. AGENCY: ACTION: Announcement is made of the availability for licensing of the invention set forth in U.S. Provisional Patent Application Serial No. 61/ 517,858, entitled ‘‘Guanidylimidazole and Guanidylimidazoline Derivatives as Antimalarial Agents, Synthesis of and Methods of Use Thereof,’’ filed on April 26, 2011. The United States Government, as represented by the Secretary of the Army, has rights to this invention. ADDRESSES: Commander, U.S. Army Medical Research and Materiel Command, Attn: Command Judge Advocate, MCMR–JA, 504 Scott Street, Fort Detrick, Frederick, MD 21702– 5012. FOR FURTHER INFORMATION CONTACT: For patent issues, Ms. Elizabeth Arwine, Patent Attorney, (301) 619–7808. For licensing issues, Dr. Paul Mele, Office of Research and Technology Applications (ORTA), (301) 619–6664, both at telefax (301) 619–5034. SUPPLEMENTARY INFORMATION: The invention relates to new guanidylimidazole derivatives and guanidylimidazoline derivatives, methods of making these compounds, compositions containing the same, and methods of using the same to prevent, treat, or inhibit malaria in a subject. The compounds have radical curative antimalarial activity. SUMMARY: Brenda S. Bowen, Army Federal Register Liaison Officer. Announcement is made of the availability for licensing of the invention set forth in U.S. Provisional Patent Application Serial No. 61/ 518,800, entitled ‘‘2-Guanidino-4-oxoImidazoline Derivatives as Antimalarial Agents, Synthesis and Methods of Use Thereof,’’ filed on April 26, 2011. The United States Government, as represented by the Secretary of the Army, has rights to this invention. ADDRESSES: Commander, U.S. Army Medical Research and Materiel Command, Attn: Command Judge Advocate, MCMR–JA, 504 Scott Street, Fort Detrick, Frederick, MD 21702– 5012. For patent issues, Ms. Elizabeth Arwine, Patent Attorney, (301) 619–7808. For licensing issues, Dr. Paul Mele, Office of Research and Technology Applications (ORTA), (301) 619–6664, both at telefax (301) 619–5034. SUPPLEMENTARY INFORMATION: The invention relates to new 2-guanidino-4oxo-imidazoline derivatives (deoxo-IZ), methods of making these compounds, compositions containing the same, and methods of using the same to prevent, treat, or inhibit malaria in a subject. The compounds have radical curative antimalarial activity. FOR FURTHER INFORMATION CONTACT: Brenda S. Bowen, Army Federal Register Liaison Officer. [FR Doc. 2011–16258 Filed 6–28–11; 8:45 am] BILLING CODE 3710–08–P DEPARTMENT OF DEFENSE Department of the Army; Corps of Engineers Intent To Prepare a Draft Environmental Impact Statement for the Currituck Sound Ecosystem Restoration Feasibility Study Department of the Army, U.S. Army Corps of Engineers. ACTION: Notice of Intent. AGENCY: [FR Doc. 2011–16291 Filed 6–28–11; 8:45 am] BILLING CODE 3710–08–P The U.S. Army Corps of Engineers (USACE) intends to prepare a Draft Environmental Impact Statement (DEIS) for the Currituck Sound Ecosystem Restoration Feasibility Study. The feasibility study is a costshared effort, being conducted in partnership with the North Carolina Division of Water Resources (NCDWR), to recommend Federal actions for ecosystem restoration in Currituck Sound. The study is taking a watershed perspective to develop and evaluate SUMMARY: DEPARTMENT OF DEFENSE mstockstill on DSK4VPTVN1PROD with NOTICES Department of the Army Notice of Availability for Exclusive, Non-Exclusive, or Partially-Exclusive Licensing of an Invention Concerning the 2-Guanidino-4-oxo-Imidazoline Derivatives as Antimalarial Agents, Synthesis of and Methods of Use Thereof AGENCY: Department of the Army, DoD. VerDate Mar<15>2010 17:48 Jun 28, 2011 Jkt 223001 PO 00000 Frm 00015 Fmt 4703 Sfmt 4703 alternatives to restore and enhance ecosystem resources in a holistic, collaborative manner, and to ensure full participation of all stakeholders. Significant environmental resources to be addressed during project studies and in the DEIS include, but are not limited to: (1) Endangered and threatened species; (2) Marine and estuarine resources; (3) Fish and wildlife and their habitats, including essential fish habitat; (4) Water quality; (5) Socioeconomic resources; and (6) Cultural resources. Efforts will be made to enhance resource conditions and minimize adverse impacts. The lead Federal agency for this study is the USACE, Wilmington District. As stated above, the NCDWR is the lead State agency and a full cost-sharing partner in the conduct of this study. The DEIS is being prepared in accordance with the requirements of the National Environmental Policy Act (NEPA) of 1969, as amended, and will address the relationship of the proposed action to all other applicable Federal and State Laws and Executive Orders. The DEIS is currently scheduled for distribution to the public February 2012. FOR FURTHER INFORMATION CONTACT: Questions about the proposed action and DEIS can be answered by Mr. Doug Piatkowski, Environmental Resources Section; U.S. Army Engineer District, Wilmington; 69 Darlington Avenue, Wilmington, North Carolina 28403; telephone (910) 251–4908. SUPPLEMENTAL INFORMATION. 1. Authority. The feasibility study is being carried out under the Corps of Engineers’ General Investigation Program and is being conducted in response to the following House resolution adopted March 11, 1998: Resolved by the Committee on Transportation and Infrastructure of the United States House of Representatives, that the Secretary of the Army is requested to review the report of the Division Engineer dated June 25, 1991, on Eastern North Carolina above Cape Lookout, North Carolina, and other pertinent reports, to determine whether modifications to the recommendations contained therein are advisable at the present time in the interest of water quality, environmental restoration and protection, and related purposes in Currituck Sound. 2. Project Purpose. The project purpose is to maintain, restore, and enhance vital aquatic habitats of the Currituck Sound to ensure the survival of wildlife and fisheries. These habitats include: the estuarine water column, wetlands including coastal marsh and shrub buffers, submerged aquatic vegetation, and bird nesting islands. E:\FR\FM\29JNN1.SGM 29JNN1

Agencies

[Federal Register Volume 76, Number 125 (Wednesday, June 29, 2011)]
[Notices]
[Page 38122]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-16291]



[[Page 38122]]

-----------------------------------------------------------------------

DEPARTMENT OF DEFENSE

Department of the Army


Notice of Availability for Exclusive, Non-Exclusive, or 
Partially-Exclusive Licensing of an Invention Concerning the 
Guanidylimidazole and Guanidylimidazoline Derivatives as Antimalarial 
Agents, Synthesis of and Methods of Use Thereof

AGENCY: Department of the Army, DoD.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: Announcement is made of the availability for licensing of the 
invention set forth in U.S. Provisional Patent Application Serial No. 
61/517,858, entitled ``Guanidylimidazole and Guanidylimidazoline 
Derivatives as Antimalarial Agents, Synthesis of and Methods of Use 
Thereof,'' filed on April 26, 2011. The United States Government, as 
represented by the Secretary of the Army, has rights to this invention.

ADDRESSES: Commander, U.S. Army Medical Research and Materiel Command, 
Attn: Command Judge Advocate, MCMR-JA, 504 Scott Street, Fort Detrick, 
Frederick, MD 21702-5012.

FOR FURTHER INFORMATION CONTACT: For patent issues, Ms. Elizabeth 
Arwine, Patent Attorney, (301) 619-7808. For licensing issues, Dr. Paul 
Mele, Office of Research and Technology Applications (ORTA), (301) 619-
6664, both at telefax (301) 619-5034.

SUPPLEMENTARY INFORMATION: The invention relates to new 
guanidylimidazole derivatives and guanidylimidazoline derivatives, 
methods of making these compounds, compositions containing the same, 
and methods of using the same to prevent, treat, or inhibit malaria in 
a subject. The compounds have radical curative antimalarial activity.

Brenda S. Bowen,
Army Federal Register Liaison Officer.
[FR Doc. 2011-16291 Filed 6-28-11; 8:45 am]
BILLING CODE 3710-08-P